Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
NCT ID: NCT04641871
Last Updated: 2024-06-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
78 participants
INTERVENTIONAL
2020-10-12
2024-06-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
NCT04672434
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941
Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors
NCT00003711
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
NCT02410512
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
NCT04972981
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Biliary tract carcinomas patients who have progressed on one prior line of gemcitabine and platinum-based chemotherapy in the metastatic setting.
* Esophageal squamous cell carcinoma patients who have progressed on one prior line of platinum-based chemotherapy in the metastatic setting.
The trial is set up as 3 sub-studies.
* Sub-study 1 includes biliary tract carcinoma patients and is composed of 2 investigational combination treatment arms (Sym021+Sym022 \[Arm A\] and Sym021+Sym023 \[Arm B\]).
* Sub-study 2, includes biliary tract carcinoma patients and is composed of one investigational combination treatment arm:Sym021+Sym023+irinotecan. A safety lead- in phase is included to assess tolerability of the combination. A Study Safety Team will review clinical and laboratory safety data and will make decisions regarding the continued enrollment after the safety lead-in phase.
* Sub-Study 3, includes esophageal squamous cell carcinoma patients and is composed of one investigational combination treatment arm: Sym021+Sym023+irinotecan. Dose of irinotecan in this arm will be selected based upon the safety lead in in sub-study 2 period.
August 2021 : Based upon results from a recent per protocol Interim Analysis (IA) it is has been decided as of 3rd of August 2021 to stop further enrollment into Sub-study 1 Arm A (Sym021+Sym022). Future patients will be allocated to either Sub-study 1 Arm B (Sym021+Sym023) or Sub-study 2 (Sym021+Sym023+irinotecan).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sym021+Sym022 [ARM A] for BTC patients
Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym022 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
Sym021
IV infusion over 30 minutes on day 1 and 15 of each cycle.
Sym022
IV infusion over 30 minutes on day 1 and 15 of each cycle.
Sym021+Sym023 [ARM B] for BTC patients
Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
Sym021
IV infusion over 30 minutes on day 1 and 15 of each cycle.
Sym023
IV infusion over 30 minutes on day 1 and 15 of each cycle.
Sym021+Sym023+irrinotecan for BTC patients
Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated. After another 30-minute post-dosing interval, irinotecan will be infused over 90 minutes.
Sym021
IV infusion over 30 minutes on day 1 and 15 of each cycle.
Sym023
IV infusion over 30 minutes on day 1 and 15 of each cycle.
Irinotecan Hydrochloride
IV infusion over 90 min on day 1 and 15 of the first 2 cycles. After 2 cycles of treatment, irinotecan may be discontinued at the Investigator's discretion
Sym021+Sym023+irrinotecan for ESCC patients
Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated. After another 30-minute post-dosing interval, irinotecan will be infused over 90 minutes.
Sym021
IV infusion over 30 minutes on day 1 and 15 of each cycle.
Sym023
IV infusion over 30 minutes on day 1 and 15 of each cycle.
Irinotecan Hydrochloride
IV infusion over 90 min on day 1 and 15 of the first 2 cycles. After 2 cycles of treatment, irinotecan may be discontinued at the Investigator's discretion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sym021
IV infusion over 30 minutes on day 1 and 15 of each cycle.
Sym022
IV infusion over 30 minutes on day 1 and 15 of each cycle.
Sym023
IV infusion over 30 minutes on day 1 and 15 of each cycle.
Irinotecan Hydrochloride
IV infusion over 90 min on day 1 and 15 of the first 2 cycles. After 2 cycles of treatment, irinotecan may be discontinued at the Investigator's discretion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with locally advanced or metastatic biliary tract carcinoma including adenocarcinoma of the intra- and/or extra-hepatic bile ducts and gallbladder carcinoma. Patients with ampullary cancers are excluded.
* Patients must only have received and progressed on or be intolerant of first-line gemcitabine and platinum-based chemotherapy in metastatic/advanced setting and should not have received prior anti-PD-(L)1 therapy. Patients with known fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement, or isocitrate dehydrogenase 1 (IDH1) mutation will be excluded. Prior anti-PD-(L)1 therapy may be allowed during the trial if regulatory approval for such therapy is obtained while this trial is enrolling.
For Sub-study 3:
* Patients with with locally advanced or metastatic esophageal squamous cell carcinoma
* Patients must only have received and progressed on or be intolerant of first-line platinum-based chemotherapy in metastatic/advanced setting and should have received prior anti-PD-(L)1 therapy. Patients with mixed adenosquamous histology cancers are excluded.
For all Sub-studies :
* Patients with measurable disease according to RECIST v1.1
* Patients with an ECOG PS of 0 or 1, and anticipated life expectancy of ≥3 months
* Patients must have adequate organ function as indicated by laboratory values
* Adequate contraception required as appropriate
Exclusion Criteria
* Patients with significant cardiovascular disease
* Patients with
1. Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks prior to the first study drug dose
2. Active uncontrolled bleeding or a known bleeding diathesis
* Patients with a significant pulmonary disease or condition
* Patients with a current or recent (within 6 months) significant gastrointestinal disease or condition
* Patients with Gilbert's syndrome or patients with UGT1A1\*28 homozygosity (also known as UGT1A1 7/7 genotype)
* Patients with a significant ocular disease or condition
* Patients with an active, known or suspected autoimmune disease
* Patients with any other serious/active/uncontrolled infection
* Patients with a history of organ transplantation
* Patients with human immunodeficiency virus (HIV) (HIV 1/2 antibodies) or active infection with hepatitis B virus or hepatitis C virus
* Prior therapy with irinotecan
* For Sub-study 1 and Sub-study 2: Anti-PD-(L)1, anti -LAG-3\* or anti-TIM-3 containing regimen, or combination with any other systemic or localized therapy or any other immuno-oncology (IO) therapies.
* For Sub-study 3: Anti-TIM-3 containing regimen, or combination with any other systemic or localized therapy or any other IO therapies (other than anti-PD-(L)1 agents).
* Patients must not be on warfarin, if they have a history of acute immune-related thrombocytopenia; patients must not be on strong cytochrome P450 (CYP) 3A4 inducers, strong CYP3A4 inhibitors, or strong UGT1A1 inhibitors.
* Patients with a known or suspected hypersensitivity to any of the excipients of formulated study drug
* Patients with unresolved \>Grade 1 toxicity associated with any prior antineoplastic therapy
* Sub-study 1 and Sub-study 2: Patients with known FGFR2 fusion or rearrangement, or IDH1 mutation.
* For Sub-study 3: Patients with a history of significant toxicities associated with previous administration of immune checkpoint inhibitors that necessitated permanent discontinuation of that therapy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Symphogen A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nehal Lakhani, MD
Role: PRINCIPAL_INVESTIGATOR
START Midwest
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Colorado
Aurora, Colorado, United States
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
University of Chicago
Chicago, Illinois, United States
University of Kansas Medical Center (KUMC)
Westwood, Kansas, United States
START Midwest
Grand Rapids, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Mount Sinai - PRIME
New York, New York, United States
Montefiore Medical Center PRIME
The Bronx, New York, United States
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
MD Anderson
Houston, Texas, United States
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Centre Georges-François Leclerc, Department of Medical Oncology
Dijon, , France
Institut de Cancerologie de L'Ouest
Saint-Herblain, , France
Vall d'Hebron Institute of Oncology
Barcelona, , Spain
Hospital Universitario San Carlos
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sym021-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.